Promed P.Lach R.Glowacki Sp. j.
- Address
- lock Available on a paid plan
Eye Diseases – Retinal Vein Occlusion
At Promed P.Lach R.Glowacki Sp. j. clinicians are investigating novel approaches for macular edema secondary to retinal vein occlusion, with the goal of enhancing visual outcomes and confirming treatment safety.
- Assessment of best‑corrected visual acuity changes
- Comparison of different intravitreal dosing schedules
- Comprehensive safety monitoring of ocular injections
The research aims to broaden therapeutic options for patients experiencing vision loss due to retinal vascular disease.
Immune System Processes – RSV Prevention
Researchers at the centre are conducting a pediatric study on respiratory syncytial virus (RSV) prevention, evaluating the safety and efficacy of a long‑acting antibody in healthy infants.
- Incidence of RSV‑associated lower respiratory infections
- Safety and tolerability assessment through adverse event tracking
- Potential to reduce outpatient and inpatient respiratory illness
Results may inform future preventive strategies and improve public health outcomes for young children.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Promed P.Lach R.Glowacki Sp. j.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aflibercept | 1 | Unknown | 2023-09-13 | 2023-09-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.